Ethio ANC

Antenatal care companion · v2.0 clinical edition

Dating calculator

GA · EDD · trimester · WHO contact schedule
Enter the Ethiopian date directly — Day / Month / Year (E.C.), just like a Gregorian date field. Results always show both calendars.

Exam pearl

Naegele's rule (LMP + 280 days) assumes a regular 28-day cycle with ovulation on day 14. First-trimester CRL is the single most accurate dating method and should generally take precedence over LMP-based dating when the discrepancy exceeds guideline thresholds (ACOG Committee Opinion 700 / SMFM 2017).

WHO 8-contact ANC schedule

WHO ANC 2016 · Ethiopia FMOH protocol

Why 8 contacts, not 4?

The 2016 WHO model replaced the older 4-visit Focused ANC package after evidence linked more contacts to fewer stillbirths and greater maternal satisfaction, without proven harm. "Contact" is used deliberately instead of "visit" to emphasize active clinician–woman engagement.

Supplementation & prevention

Dosing reference across all contacts
InterventionDose / regimenTimingGuideline
Iron + folic acid (IFA)30–60 mg elemental iron + 0.4 mg folic acid, dailyStart at booking, continue through pregnancy; intermittent (weekly) IFA is an alternative where daily adherence/anemia prevalence is lowWHO ANC 2016
Calcium1.5–2 g elemental calcium/day (divided doses, separate from iron)From 20 weeks in populations with low dietary calcium intakeWHO 2018 update (pre-eclampsia prevention)
Low-dose aspirin75–162 mg once daily (evening dosing favored)Start 12–16 weeks (before 16w ideally) if ≥1 high-risk or ≥2 moderate-risk factor for pre-eclampsia; continue to deliveryACOG / USPSTF 2021
Tetanus toxoid (TT)TT1 at first contact if unimmunized → TT2 ≥4 weeks later → TT3 ≥6 months → TT4 ≥1 yr → TT5 ≥1 yr (lifelong protection after TT5)Per national EPI scheduleWHO EPI
DewormingAlbendazole 400 mg or Mebendazole 500 mg, single doseAfter the 1st trimester, in endemic areasWHO
IPTp-SP (malaria)Sulfadoxine-pyrimethamine, single clearance doseStarting 13 weeks, doses ≥4 weeks apart, at each scheduled contact, in moderate–high transmission areasWHO malaria in pregnancy policy
Insecticide-treated net (ITN)Provide/reinforce useAt booking, malaria-endemic areasWHO
Anti-D immunoglobulin300 mcg (1500 IU) IM~28 weeks routinely if Rh(D)-negative & unsensitized; repeat after any sensitizing event and postpartum if baby is Rh-positiveACOG Practice Bulletin 181

High-yield distinction

Folic acid dose for routine ANC prophylaxis is 0.4 mg/day — this is different from the 4–5 mg/day high dose used for women with a prior neural-tube-defect-affected pregnancy or on antiepileptics, which should start ≥1 month pre-conception and continue through the first trimester.

Danger signs & screening

Patient-facing alerts + clinician lab workup

Danger signs in pregnancy — seek care immediately

  • Vaginal bleeding, any amount
  • Severe headache with blurred vision
  • Convulsions / fits
  • Severe abdominal or epigastric pain
  • Fast or difficult breathing
  • Fever
  • Severe or persistent vomiting
  • Reduced or absent fetal movements
  • Watery vaginal leakage (possible ruptured membranes)
  • Sudden swelling of face, hands, or legs

Source: WHO ANC 2016 recommendations; adapted to Ethiopian FMOH ANC protocol patient-education materials.

Booking-visit laboratory panel

Universal
  • CBC / Hb (anemia screen)
  • Blood group & Rh(D)
  • Urinalysis: protein, glucose, nitrites
  • HIV testing (opt-out, per national policy)
  • Syphilis: RPR/VDRL or point-of-care treponemal test
  • HBsAg per national policy
Risk-based / trimester-specific
  • 75 g OGTT for GDM — universal or risk-based, 24–28 weeks
  • Recto-vaginal GBS swab — 36–37 weeks (where resources allow)
  • Repeat Hb — 3rd trimester
  • Malaria RDT/microscopy if febrile, endemic area
  • Urine culture if symptomatic or recurrent bacteriuria

Gestational diabetes — diagnostic thresholds

TimepointIADPSG / WHO 2013 one-step (75 g OGTT)
Fasting≥ 92 mg/dL (5.1 mmol/L)
1 hour≥ 180 mg/dL (10.0 mmol/L)
2 hour≥ 153 mg/dL (8.5 mmol/L)

Any one abnormal value is diagnostic. The two-step approach (50 g screen → 100 g diagnostic, Carpenter–Coustan criteria) remains an accepted alternative in some settings, including much of US practice (ACOG).

Fetal development timeline

ACOG · WHO · RCOG
Weeks 1–8 (1st trimester): Foundational organogenesis; cardiac activity is typically detectable by transvaginal ultrasound around 6 weeks.ACOG FAQ156
Weeks 9–12: Major organs and systems continue developing; early movement begins though not yet perceived by the mother.ACOG FAQ156
Weeks 13–16: Skeletal ossification progresses; movements become more coordinated.ACOG FAQ156
Weeks 16–20: Maternal perception of movement ("quickening") — usually 18–20 weeks in nulliparas, slightly earlier in multiparas.RCOG patient information
Weeks 18–22: Detailed anomaly ultrasound window — fetal anatomic survey and dating/placental confirmation.WHO ANC 2016; ISUOG practice guideline
~23–24 weeks: Conventional lower threshold of viability in many high-resource settings, with survival highly dependent on level of neonatal care available.AAP/ACOG periviability consensus
~28 weeks: Cortical brain networks are still largely localized; reflex responses to stimuli become measurable.RCOG Fetal Awareness review 2022
~30+ weeks: Long-range functional brain connectivity increases; sleep–wake organization of movement emerges.RCOG Fetal Awareness review 2022
Term (37–40+ weeks): Fetal movement should continue through labor; any reduction should be reported promptly.RCOG patient information
References
  1. ACOG. How Your Fetus Grows During Pregnancy, FAQ156.
  2. WHO. Recommendations on antenatal care for a positive pregnancy experience (2016).
  3. RCOG. Fetal Awareness: Updated Review of Research and Recommendations for Practice (2022).

Hypertensive disorders of pregnancy

Definitions · decision engine · MgSO4 · BP control

Definitions (ACOG 2020 / ISSHP 2018)

Gestational hypertension
SBP ≥140 or DBP ≥90 mmHg on two occasions ≥4 h apart, after 20 weeks, in a previously normotensive woman, without proteinuria or severe features. Roughly 15–25% progress to pre-eclampsia.
Pre-eclampsia
Gestational hypertension plus new onset of any one of:
  • Proteinuria ≥300 mg/24h, protein/creatinine ratio ≥0.3, or dipstick 2+ if quantitative testing unavailable
  • or, in the absence of proteinuria: thrombocytopenia (platelets <100×10&sup9;/L), renal insufficiency (creatinine >1.1 mg/dL or doubling of baseline), impaired liver function (transaminases ≥2× normal), pulmonary edema, or new-onset headache/visual symptoms unresponsive to medication and not explained by an alternative diagnosis
Pre-eclampsia with severe features
Any of: SBP ≥160 or DBP ≥110 mmHg (confirmed on repeat), platelets <100×10&sup9;/L, creatinine >1.1 mg/dL or doubling, transaminases ≥2× ULN with severe persistent RUQ/epigastric pain, pulmonary edema, or new cerebral/visual symptoms. Proteinuria is not required to diagnose severe features.
Eclampsia & HELLP
Eclampsia: new-onset generalized seizures in a woman with pre-eclampsia, without another identifiable cause. HELLP syndrome: Hemolysis, Elevated Liver enzymes, Low Platelets — a severe variant that may occur with only modestly elevated BP.

Common pitfall

Hypertension alone (without proteinuria or another severe feature) is gestational hypertension, not pre-eclampsia. Conversely, severe features (e.g., BP ≥160/110 or thrombocytopenia) upgrade the diagnosis to severe pre-eclampsia even if the urine dipstick is negative.

Bedside classification engine

Educational decision support only — always correlate with the full clinical picture; this is not a substitute for clinical judgment.

MgSO4 toxicity — know the antidote

Loss of patellar reflex is usually the earliest sign of magnesium toxicity, followed by respiratory depression (RR <12/min) and, at higher levels, cardiac arrest. Antidote: calcium gluconate 1 g (10 mL of 10%) IV over 10 minutes. Hold/reduce the dose if urine output <25–30 mL/h, since magnesium is renally cleared.

Title